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This study was conducted to compare long-term outcomes in patients with refractory/relapsed grades 1 and 2
follicular lymphoma (FL) after allogeneic (allo) versus autologous (auto) hematopoietic cell transplantation
(HCT) in the rituximab era. Adult patients with relapsed/refractory grades 1 and 2 FL undergoing ﬁrst
reduced-intensity allo-HCT or ﬁrst autograft during 2000 to 2012 were evaluated. A total of 518 rituximab-
treated patients were included. Allo-HCT patients were younger and more heavily pretreated, and more
patients had advanced stage and chemoresistant disease. The 5-year adjusted probabilities, comparing auto-
HCT versus allo-HCT groups for nonrelapse mortality (NRM) were 5% versus 26% (P < .0001); relapse/pro-
gression: 54% versus 20% (P < .0001); progression-free survival (PFS): 41% versus 58% (P < .001), and overall
survival (OS): 74% versus 66% (P ¼ .05). Auto-HCT was associated with a higher risk of relapse/progression
beyond 5 months after HCT (relative risk [RR], 4.4; P < .0001) and worse PFS (RR, 2.9; P < .0001) beyond 11
months after HCT. In the ﬁrst 24 months after HCT, auto-HCT was associated with improved OS (RR, .41; P <
.0001), but beyond 24 months, it was associated with inferior OS (RR, 2.2; P ¼ .006). A landmark analysis of
patients alive and progression-free at 2 years after HCT conﬁrmed these observations, showing no difference
in further NRM between both groups, but there was signiﬁcantly higher risk of relapse/progression (RR, 7.3; P
< .0001) and inferior PFS (RR, 3.2; P < .0001) and OS (RR, 2.1; P ¼ .04) after auto-HCT. The 10-year cumulative
incidences of second hematological malignancies after allo-HCT and auto-HCT were 0% and 7%, respectively.
Auto-HCT and reduced-intensityeconditioned allo-HCT as ﬁrst transplantation approach can provide durable
disease control in grades 1 and 2 FL patients. Continued disease relapse risk after auto-HCT translates into
improved PFS and OS after allo-HCT in long-term survivors.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION Historically, myeloablative allo-HCTs in FL were associ-
Follicular lymphoma (FL), with its long natural history
and indolent course, is a heterogeneous malignancy.
Although many patients survive for decades, a signiﬁcant
portion have a more aggressive course andw20% of patients
die within 2 to 3 years of diagnosis. For patients with
repeated relapses and short remissions, hematopoietic cell
transplantation (HCT) remains a vital tool. However, there is
continued debate on the optimal timing and most effective
HCT modality. Autologous (auto) HCT is frequently per-
formed in patients with relapsed/refractory FL, but therapy
failure remains a challenge [1-3]. To mitigate the relapse risk,
allogeneic (allo) HCT is often considered in relapsed/re-
fractory FL [4]. Whether auto-HCT or allo-HCT represent the
preferred ﬁrst transplantation approach in FL remains to be
determined, especially in the rituximab era. In pre-rituximab
era, the EBMT (European Group for Blood and Marrow
Transplantation) Chemotherapy, Unpurged or Purged auto-
HCT (CUP) Trial showed a progression-free survival (PFS)
and overall survival (OS) beneﬁt for auto-HCTcomparedwith
salvage chemotherapy alone in relapsed FL [5]. Some but not
all retrospective studies from the pre-rituximab era have
shown durable disease control after auto-HCT, especially
among FL patients in ﬁrst or second complete remission (CR)
[1,6,7]. Unfortunately similar randomized or retrospective
data in the rituximab era are not available. The post hoc
analysis of 2 successive Groupe d’Etude des Lymphomes
Folliculaires (GELF-86/-94) trials suggest that in relapsed FL
patients receiving rituximab-containing salvage therapies,
auto-HCT does not provide a PFS or OS advantage compared
with chemoimmunotherapy alone, with neither strategy
resulting in apparent cures [8]. Furthermore, the risk of
second malignancies after auto-HCT is not insigniﬁcant,
ranging from 5% to 20% [1,2].
Allo-HCT provides a lymphoma-free graft devoid of prior
chemotherapy-induced DNA damage and has the potential to
mediate a graft-versus-lymphoma (GVL) effect. Allo-HCT has
been shown to confer long-term remissions in patients with
FL, with a plateau for PFS after 2 to 3 years from trans-
plantation, suggesting clinical evidence of durable GVL ef-
fects and likely cure [9-12].ated with increased nonrelapse mortality (NRM) (w30% to
40%) [12,13]. To exploit the beneﬁcial GVL effects without
high rates of NRM, reduced-intensity/nonmyeloablative
conditioning (RIC/NMA) HCTs have been widely adopted
[11,14-16]. However, as the toxicity of RIC allo-HCT still re-
mains higher than that of auto-HCT, the question arises
whether the potential beneﬁt of the GVL effects associated
with the allo-HCT justiﬁes its application as the ﬁrst trans-
plantation approach in FL. The only prospective comparison
between auto-HCT and allo-HCT for relapsed FL performed
by Bone and Marrow Transplantation Clinical Trials Network
closed early because of poor accrual [17]. A recent retro-
spective EBMT study did not show improved OS in FL pa-
tients after RIC allo-HCT compared to auto-HCT when either
modality was applied as the ﬁrst transplantation procedure
[18]. However, > 50% of patients in the EBMT analysis never
received rituximab before HCT, a scenario that is no longer
clinically relevant.
We utilized the Center for International Blood and
Marrow Transplant Research (CIBMTR) registry to assess the
relative efﬁcacy of auto-HCT against RIC/NMA allo-HCT,
when either modality is used as the ﬁrst transplantation
procedure, in relapsed/refractory FL in the rituximab era.
PATIENTS AND METHODS
Data Sources
The CIBMTR is a working group of more than 450 transplantation cen-
ters worldwide that contribute detailed data on HCTs to a statistical center at
the Medical College of Wisconsin. Centers report HCTs consecutively, with
compliance monitored by on-site audits. Patients are followed longitudi-
nally with yearly follow-up. Observational studies by the CIBMTR are per-
formed in compliance with federal regulations with ongoing review by the
institutional review board of the Medical College of Wisconsin.
Patients
Patients with a histologically proven diagnosis of relapsed/refractory
grade 1 or 2 FL, undergoing a ﬁrst auto-HCT or a ﬁrst RIC/NMA allo-HCT,
reported to the CIBMTR between 2000 and 2012 were eligible. RIC/NMA
allo-HCT patients with a history of prior auto-HCT were not included. Donor
source for the allo-HCT cohort was restricted to either HLA-identical siblings
or at least a 7/8 (antigen or allele-level)-matched unrelated donors (URD).
Pediatric patients (<18 years), those undergoing alternative donor HCT (eg,
umbilical cord blood, haploidentical, mismatched URD), and patients
Table 1
Characteristics of Patients Who Underwent Auto-HCT or RIC-allo-HCT for Relapsed/Refractory Grades 1 or 2 FL from 2000 to 2012 Reported to the CIBMTR
Variable Allo-HCT Auto-HCT P Value
No. of patients 268 250
Age at HCT, mean/median (range), yr 51.7/52 (27-74) 53.7/54 (22-79) .01
Male gender 149 (56) 147 (59) .46
Karnofsky performance score
<90% 62 (23) 56 (22) .06
90%-100% 193 (72) 168 (67)
Missing 13 (5) 26 (10)
Race
Caucasian/White 241 (90) 227 (91) .12
Black 7 (3) 5 (2)
Others 20 (7) 18 (7)
Disease stage at diagnosis
I-II 38 (14) 59 (24) <.001
III-IV 217 (81) 185 (74)
Unknown 13 (5) 6 (2)
Histological grade
1 143 (53) 115 (46) .09
2 125 (47) 135 (54)
Time from diagnosis to HCT, median (range), mo 43 (4-352) 34 (6-315) .001
B symptoms at diagnosis 89 (33) 82 (33) .25
Elevated LDH at HCT 79 (29) 72 (29) .10
Unknown 22 (8) 35 (14)
Bulky disease at diagnosis 25 (9) 20 (8) .17
Bone marrow involvement at HCT 39 (15) 10 (4) <.001
Missing 200 (75) 212 (85)
Extranodal involvement at HCT 70 (26) 40 (16) .002
Missing 10 (4) 3 (1)
Rituximab resistant 118 (44) 161 (64) <.001
Not evaluable 22 (8) 9 (4)
Chemotherapy lines, median (range) 4 (1-5) 3 (1-5) .001
Anthracycline-based therapies before HCT 188 (70) 207 (83) .001
Platinum-based therapies before HCT 91 (34) 87 (35) .84
Duration of ﬁrst-line therapy response
<1 Yr 79 (29) 68 (27) .76
1 Yr 173 (65) 164 (66)
Missing 16 (6) 18 (7)
History of radiation therapy before HCT 54 (20) 54 (22) .68
History of doxorubicin-based therapies 188 (70) 207 (83) .001
Disease response at transplantation
CR 87 (32) 108 (43) <.001
PR 115 (43) 118 (47)
Chemoresistant/untreated relapse 66 (25) 24 (10)
Donor type
HLA-identical sibling 143 (53) N/A N/A
Unrelated well-matched (8/8 alleles) 103 (38)
Unrelated partially matched (7/8 antigens or 7/8 alleles) 22 (8)
TBI-based conditioning 48 (18) 36 (14) .28
Conditioning regimens (Allo-HCT)
TBI low dose (<500 cGY single or <800 cGY fractionated) 9 (3) N/A N/A
Melphalan  150 mg/m2 44 (16)
Busulfan  9 mg/kg (with TBI n ¼ 5) 66 (25)
TBI 200cGY þ ﬂudarabine 35 (13)
Fludarabine/cyclophosphamide 108 (40)
Fludarabine/cytarabine 1 (<1)
CBV 5 (2)
Conditioning regimens Auto-HCT)
TBI-based N/A 36 (14) N/A
BEAM and similar 170 (68)
CBV or similar 33 (13)
BuMEL/BuCy 7 (3)
Others* 4 (2)
Graft type
Bone marrow 27 (10) 0 <.001
Peripheral blood 241 (90) 250
GVHD prophylaxis
Tacrolimus-based 194 (72) N/A N/A
Cyclosporine-based 67 (25)
Othersy 7 (2)
ATG or alemtuzumab used 53 (20) N/A N/A
CR, complete remission; LDH indicates lactate dehydrogenase; GVHD, graft versus host disease; HCT, hematopoietic cell transplantation; PR, partial remission;
TBI, total body irradiation; N/A, not applicable; CBV, cyclophosphamide/carmustine/etoposide; BEAM, carmustine, etoposide, cytarabine, melphalan; BuMEL,
busulfan/melphalan; BuCy, busulfan, cyclophosphamide; ATG, antithymocyte globulin.
* Busulfan only (n ¼ 1), busulfan þ ﬂudarabine (n ¼ 1), melphalan alone (n ¼ 1) and melphalan þ mitoxantrone (n ¼ 1).
y Other GVHD prophylaxis: steroids þmethotrexate (MTX) (n ¼ 1), steroids þMTX þMMF (n ¼ 1), steroids þMTX þ sirolimus (n ¼ 1), monoclonal þMMF
(n ¼ 1) not speciﬁed (n ¼ 3).
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Table 2
Results of Univariate Analysis
Outcomes Allo-HCT (n ¼ 268) Auto-HCT (n ¼ 250) P
Value
n Eval Prob (95% CI) n Eval Prob (95% CI)
ANC recovery 
.5  109/L
268 245
28 D 97 (93-98)% 99 (96-100)% .07
100 D 99 (96-100)% 99 (96-100)% .99
Platelet recovery 
20  109
205 112
28 D 89 (84-93)% 84 (75-90)% .19
100 D 92 (87-95)% 95 (89-98)% .19
Acute GVHD (II-IV) 268 N/A
100 D 28 (23-34)%
Chronic GVHD 262 N/A
1 Yr 46 (39-52)%
3 Yr 60 (53-65)%
5 Yr 60 (54-66)%
Second malignancy 260 232
1 Yr 2 (1-4)% 0 (0-2)% .21
3 Yr 4 (2-7)% 5 (2-8)% .60
5 Yr 8 (5-13)% 5 (3-9)% .22
Second hematologic
malignancy
260 232
1 Yr 0% 0% N/A
3 Yr 0 (0-2)% 2 (1-5)% .15
5 Yr 0 (0-2)% 2 (1-5)% .15
10 Yr 0 (0-2)% 7 (2-17)% .12
Adjusted
probabilities
NRM 265 249
1 Yr 19 (14-23)% 3 (1-5)% <.001
3 Yr 23 (17-28)% 2 (1-6)% <.001
5 Yr 26 (20-31)% 5 (2-7)% <.001
Relapse/progression 265 249
1 Yr 13 (10-17)% 22 (17-27)% .005
3 Yr 19 (14-24)% 44 (38-51)% <.001
5 Yr 20 (15-24)% 54 (48-60)% <.001
PFS 265 249
1 Yr 70 (65-76)% 74 (69-80)% .31
3 Yr 61 (55-67)% 51 (45-57)% .02
5 Yr 58 (52-64)% 41 (34-47)% <.001
OS 267 249
1 Yr 77 (72-82)% 91 (88-95)% <.001
3 Yr 69 (63-74)% 82 (77-87)% <.001
5 Yr 66 (60-71)% 74 (68-79)% .05
ANC indicates neutrophil recovery.
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were not included in the analysis. In addition FL patients undergoing his-
tological transformation to diffuse large B cell lymphoma and those not
receiving rituximab-containing therapies before HCT were excluded.Deﬁnitions
The intensity of allo-HCT conditioning regimens was categorized
RIC/NMA using consensus criteria [19]. Previously established criteria
for categorizing the degree of HLA matching were used [20] for URD
transplantations. CR to last therapy line before HCT on CIBMTR forms is
deﬁned as complete resolution of all known disease on radiographic
(computed tomography scan) assessments, whereas partial remission is
deﬁned as 50% reduction in the greatest diameter of all sites of known
disease and no new sites of disease. Resistant disease is deﬁned as <50%
reduction in the diameter of all disease sites or development of new
disease sites. Rituximab resistance was deﬁned as (1) failure to achieve at
least a partial remission to a rituximab-containing therapy line or (2)
relapse/progression during or within 6 months of ﬁnishing a rituximab-
based therapy [21].Study Endpoints
Primary outcomes were NRM, progression/relapse, PFS, and OS. NRM
was deﬁned as death without evidence of lymphoma progression/relapse;
relapse was considered a competing risk. Progression/relapsewas deﬁned as
progressive lymphoma after HCT or lymphoma recurrence after a CR; NRM
was considered a competing risk. For PFS, a patient was considered atreatment failure at the time of progression/relapse or death from any cause.
Patients alive without evidence of disease relapse or progression were
censored at last follow-up. The OSwas deﬁned as the interval from the date
of transplantation to the date of death or last follow-up. Acute graft-versus-
host disease (GVHD) was deﬁned and graded based on the pattern and
severity of organ involvement using established criteria [22]. Chronic GVHD
was deﬁned as the development of any evidence of chronic GVHD based on
clinical criteria [23]. Neutrophil recovery was deﬁned as the ﬁrst of 3 suc-
cessive days with absolute neutrophil count  500/mL after post-
transplantation nadir. Platelet recovery was considered to have occurred on
the ﬁrst of 3 consecutive days with platelet count 20,000/mL or higher, in the
absence of platelet transfusion for 7 consecutive days. For neutrophil and
platelet recovery, death without the event was considered a competing risk.Statistical Analysis
Adjusted probabilities of PFS and OS were calculated as described pre-
viously [24]. Adjusted cumulative incidences of NRM, lymphoma progres-
sion/relapse, hematopoietic recovery, and second malignancies were
calculated to accommodate for competing risks [25]. Patient-, disease-, and
transplantation-related factors were compared between auto-HCT and allo-
HCT groups using the chi-square test for categorical variables and the Wil-
coxon sample test for continuous variables. Associations among patient-,
disease-, and transplantation-related variables and outcomes of interest
were evaluated using Cox proportional hazards regression. Backward
elimination was used to identify covariates that inﬂuenced outcomes.
Covariates with a P < .05 were considered signiﬁcant. The proportional
hazards assumption for Cox regression was tested by adding a time-
dependent covariate for each risk factor and each outcome. Covariates
violating the proportional hazards assumption were added as time-
dependent covariates in the Cox regression model. Interactions between
the main effect and signiﬁcant covariates were examined. Results are
expressed as relative risk (RR). All analyses were performed using SAS 9.3.
The variables considered in multivariate analysis are shown in
Supplemental Table 1S.RESULTS
Patients’ Characteristics
Between 2000 and 2012, a total of 250 patients with
relapsed/refractory grades 1 or 2 FL undergoing a ﬁrst auto-
HCT and 268 undergoing a ﬁrst RIC-allo-HCT met the inclu-
sion criteria. Patient-, disease-, and transplantation-related
characteristics are detailed in Table 1. Recipients of allo-
HCT were younger and more heavily pretreated, had more
advanced stage disease and longer intervals between diag-
nosis and HCT, had more frequent extranodal involvement,
and were more likely to be chemoresistant before HCT,
compared with recipients of auto-HCT. There was no signif-
icant difference in duration of remission to ﬁrst-line therapy
between groups.Engraftment and GVHD
The cumulative incidences of neutrophil and platelet
engraftment were similar between both groups (Table 2).
The cumulative incidence of acute GVHD (grade II to IV) at
day þ100 was 28% (95% conﬁdence interval [CI], 23% to 34%),
and the cumulative incidence of chronic GVHD at 5 years
after HCT was 60% (95% CI, 54% to 66%). GVHD was the most
frequent cause of death in the allo-HCT group (Supplemental
Table 2S).NRM
Seventy-four patients in the allo-HCT group and 27 in the
auto-HCT group experienced NRM (Supplemental Table 2S).
The 5-year adjusted probability of NRM was signiﬁcantly
higher in the allo-HCT group (26% versus 5%; P < .001)
(Table 2, Figure 1A). On multivariate analysis, auto-HCT (RR,
.21; 95% CI, .12 to .37; P < .0001) and normal lactate dehy-
drogenase level (RR, .55; P ¼ .02) were associated with lower
NRM, whereas age  60 years (RR, 3.47; P ¼ .02) and
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Figure 1. Survival outcomes for all patients (n ¼ 518). (A) Adjusted probabilities for NRM (5 years; P < .001). (B) Adjusted probabilities for relapse (5 years; P < .001).
(C) Adjusted probabilities for PFS (5 years; P < .001). (D) Adjusted probabilities for OS (5 years; P ¼ .05).
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associated with higher NRM (Table 3).Disease Progression/Relapse
The adjusted probability of disease progression/relapse at
5 years was signiﬁcantly higher in the auto-HCT group (54%
versus 20%; P < .001) (Table 2, Figure 1B). In multivariate
models, the main effect (auto-HCT versus allo-HCT) dis-
played a time-varying effect on the risk of lymphoma pro-
gression/relapse. During the ﬁrst 5 months after
transplantation, no difference between the 2 groups was
seen in terms of progression/relapse risk (RR, .80; 95% CI, .44
to 1.44; P ¼ .45). Beyond 5 months, auto-HCT was associated
with a higher risk of progression/relapse (RR, 4.38; 95% CI,
2.87 to 6.68; P < .0001). Other factors associated with
reduced risk of progression/relapse included duration of
ﬁrst-line therapy response 1 year and absence of extra-
nodal involvement at transplantation (Table 3). Relapse/
progression was the most frequent cause of death in the
auto-HCT group (Table 2S).PFS
The adjusted probability of 5-year PFS was signiﬁcantly
better after allo-HCT (58% versus 41%; P < .001) (Table 2,
Figure 1C). On multivariate analysis, the main effect (auto-
HCT versus allo-HCT) displayed a time-varying effect on the
risk of treatment failure. During the ﬁrst 11 months after
HCT, auto-HCT was associated a marginally reduced risk of
treatment failure (RR, .70; 95% CI, .49 to .99; P ¼ .05). But
beyond 11 months, auto-HCT was associated with signiﬁ-
cantly higher risk of treatment failure (ie, inferior PFS) (RR,
2.92; 95% CI, 1.99 to 4.28; P < .0001). Other factors predictive
of improved PFS in the whole cohort were chemosensitive
disease and absence of extranodal involvement at trans-
plantation (Table 3).OS
The median follow-up was similar in both groups (61
months; range, 3 to 169). In the univariate analysis, the 5-
year adjusted probabilities of OS for the auto-HCT and allo-
HCT groups were 74% and 66% (P ¼ .05), respectively
(Table 2, Figure 1D). In the multivariate analysis, within the
ﬁrst 24 months after transplantation, auto-HCT was associ-
ated with reduced risk of mortality (ie, improved OS) (RR,
.41; 95% CI, .27 to .62; P < .0001). In contrast, beyond 24
months, auto-HCT was associated with a higher risk for
mortality (ie, inferior OS) (RR, 2.21; 95% CI, 1.25 to 3.93; P ¼
.006). Other factors positively affecting OS in the whole
cohort were younger age (<60 years), absence of extranodal
involvement, and HCT performed from 2008 onwards
(Table 3).Allo-HCT Outcomes according to Donor Type
NRM, disease progression/relapse, PFS, and OS after allo-
HCT, stratiﬁed according to donor source are shown in
Table 4.Landmark Analysis in Long-Term Survivors
To further evaluate the time-varying effect seen on
multivariate models, we performed a landmark analysis,
including only patients surviving at least 24 months after
HCT without disease progression/relapse (Table 5, Figure 2).
When starting the analysis from the 24-month post-HCT
time point, we observed no signiﬁcant difference in the
risk of NRM between auto-HCT and allo-HCT (RR, .90; P ¼
.82). Auto-HCT was found to be associated with a signiﬁ-
cantly increased risk of progression/relapse (RR, 7.35; 95% CI,
3.10 to 17.42; P < .0001), treatment failure (RR, 3.23; 95% CI,
1.87 to 5.58; P < .0001) (Figure 2A), and mortality (RR, 2.09;
95% CI, 1.04 to 4.22; P ¼ .04) (Figure 2B). Among patients
surviving 24 months after HCT without disease progression/
relapse, 35 subjects died (allo-HCT, n¼ 13; and auto-HCT, n¼
22). The most common cause of death in allo-HCTcohort was
Table 3
Results of Multivariate Analysis
Variable n Relative
Risk
95% CI
Lower
Limit
95% CI
Upper
Limit
P
Value
NRM
Allo-HCT 265 1
Auto-HCT 249 .21 .12 .37 <.0001
Age at HCT, yr
<40 48 1
40-49 145 1.85 .63 5.38 .26
50-59 200 2.02 .71 5.77 .20
60 121 3.47 1.19 10.09 .02
KPS
90% 360 1
<90% 115 1.85 1.14 3.02 .01
Missing 39 2.14 .99 4.60 .05
Elevated LDH
Yes 148 1
No 309 .55 .34 .90 .02
Missing 57 .98 .46 2.12 .97
Progression/relapse
5 Mo
Allo-HCT 265 1
Auto-HCT 249 .80 .44 1.44 .45
>5 Mo
Allo-HCT 206 1
Auto-HCT 217 4.38 2.87 6.68 <.0001
Duration of ﬁrst-line
therapy response
<1 Yr 144 1
1 Yr 336 .66 .48 .91 .01
Missing 34 .88 .48 1.62 .69
Extranodal involvement
Yes 107 1
No 394 .47 .34 .67 <.0001
Missing 13 1.34 .60 2.99 .47
PFS
11 Mo
Allo-HCT 265 1
Auto-HCT 249 .70 .49 .99 .05
>11 Mo
Allo-HCT 179 1
Auto-HCT 192 2.92 1.99 4.28 <.0001
Chemosensitivity at HCT
CR 195 1
PR 231 1.13 .84 1.51 .42
Chemoresistant/untreated 88 1.59 1.1 2.29 .01
Extranodal involvement
Yes 107 1
No 394 .53 .40 .72 <.0001
Missing 13 .81 .39 1.68 .56
OS
24 Mo
Allo-HCT 267 1
Auto-HCT 249 .41 .27 .62 <.0001
>24 Mo
Allo-HCT 168 1
Auto-HCT 198 2.22 1.25 3.93 .006
Age, yr
<40 48 1
40-49 146 1.50 .75 3.03 .25
50-59 201 2.02 1.04 3.94 .04
60 121 2.84 1.43 5.66 .003
Extranodal involvement
Yes 109 1
No 394 .42 .30 .58 <.0001
Missing 13 .59 .23 1.48 .26
Year of HCT
2000-2003 117 1
2004-2007 233 1.11 .77 1.61 .57
2008 166 .58 .37 .92 .02
KPS indicates Karnofsky performance score.
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cause of death for the auto-HCT group (n ¼ 11). Detailed
causes of death of patients included in the landmark analysis
are shown in Supplemental Table 3S.Second Malignancies
The 5-year cumulative incidence of second malignancies
did not differ signiﬁcantly (allo-HCT, 8%; auto-HCT, 5%; P ¼
.22) (Table 2; in detail, Supplemental Table 4S). Non-
melanoma skin cancers were the most frequent second
malignancy type in both groups when only nonhematologic
malignancies were considered. The 10-year cumulative in-
cidences of second hematological malignancies for the allo-
HCT and auto-HCT cohorts were 0% and 7%, respectively.
Four (4%) patients in the allo-HCT group and 8 (10%) patients
in the auto-HCT group died because of a second malignancy
(Table 2S).DISCUSSION
In the current study, we assessed the roles of auto-HCT
versus allo-HCT as the ﬁrst transplantation strategy in
rituximab-treated grades 1 and 2 FL, and we make several
important observations. First, despite a higher initial NRM,
allo-HCT provides a survival beneﬁt in long-term survivors.
Second, in 2-year survivors, auto-HCT was associated with
higher relapse risk and inferior PFS and OS. Third, disease
relapse 2 to 3 years after allo-HCT was rare, but no such
plateau for auto-HCT was identiﬁed. Fourth, HCT survival in
the most recent era (2008 onwards) has improved. Finally,
risk of hematological second malignancies was largely
conﬁned to auto-HCT.
The EBMT registry study comparing ﬁrst auto-HCT with
ﬁrst RIC allo-HCT in relapsed FL showed signiﬁcantly
increased toxicity after allo-HCT due to infectious compli-
cations and GVHD [18]. Allo-HCT was associated with
improved PFS, but OS did not differ signiﬁcantly between the
2 groups. However, the EBMT analysis covered an earlier
period (1998 to 2005) and >50% of included patients were
rituximab naïve. In contrast, the present CIBMTR analysis
spanned amore recent era (2000 to 2012), andwas restricted
to rituximab-treated patients with grade 1 and 2 histologies
to minimize biologic heterogeneity. Unlike as done in prior
studies, we also analyzed the duration of disease control
after ﬁrst-line therapies, number of prior therapy lines, and
the presence of rituximab resistance before HCT to assess
therapy differences across the 2 cohorts to adjust for them in
our multivariate models.
The observed lower NRM, increased relapse risk, and
inferior PFS after auto-HCT in our analysis, are generally in
line with published data [12,18,26]. Unlike previous retro-
spective studies with long-term follow-up, where the ma-
jority of included patients were rituximab naïve [1,2,6,7], we
found no plateau in PFS of FL patients after auto-HCT.
Crossing adjusted survival curves (Figure 1C,D) 5 to 6 years
after transplantation in our study underscores the impor-
tance of mature follow-up in assessing long-term outcomes
in FL. Further, in agreement with previous studies [11,12,18],
the allograft recipients in our study had improved PFS,
achieving a plateau 2 to 3 years after transplantation.
Advanced patient age, lower Karnofsky performance score,
Table 4
Univariate Outcomes after Allo-HCT Stratiﬁed according to Donor Type
Outcomes HLA-identical Siblings
(N ¼ 143)
8/8 Allele-matched URD
(N ¼ 103)
<8/8 URD (N ¼ 22) P Value
n Eval Prob (95% CI) n Eval Prob (95% CI) n Eval Prob (95% CI)
NRM mortality 143 101 22
1 yr 14 (9-21)% 21 (13-29)% 23 (8-42)% .34
3 yr 18 (12-25)% 25 (17-34)% 23 (8-42)% .43
5 yr 20 (14-28)% 30 (21-40)% 23 (8-42)% .30
Progression/relapse 143 101 22
1 yr 15 (10-21)% 15 (9-23)% 5 (0-19)% .13
3 yr 20 (13-27)% 23 (15-32)% 9 (1-26)% .23
5 yr 20 (13-27)% 24 (16-33)% 9 (1-26)% .18
PFS 143 101 22
1 yr 71 (63-78)% 64 (55-73)% 72 (52-89)% .52
3 yr 62 (54-70)% 52 (42-62)% Not evaluable .20
5 yr 60 (51-68)% 46 (36-57)% Not evaluable .06
OS 143 103 22
1 yr 77 (70-84)% 76 (67-83)% 73 (53-89)% .88
3 yr 70 (62-77)% 65 (55-74)% 73 (53-89)% .68
5 yr 67 (59-75)% 60 (50-69)% 73 (53-89)% .36
Outcomes of <8/8 alleleematched group showed be interpreted with caution, considering the small sample size.
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with increased NRM, in line with earlier reports [12,26].
In a small series of patients with indolent lymphoma (n¼
112), Hosing et al. observed crossing OS curves after auto-
HCT and allo-HCT at 5 years after transplantation, suggest-
ing improved survival for allo-HCT [10]. In the current study,
we focused on the outcomes of long-time survivors (24
months). Our landmark analysis showed that beyond 2 years
after HCT, the early beneﬁt of NRM with auto-HCT was no
longer present, but the sustained lower relapse/progression
rates after allo-HCT translated into long-term PFS and OS
beneﬁt in favor of allografting. The lower risk of relapse/
progression after allo-HCT on multivariate models becomes
apparent 5 months after transplantation. This somewhat
delayed effect could be explained by intensive immunosup-
pression during the ﬁrst few months after HCT that may
attenuate the development of the GVL effect early after allo-
HCT, or alternately, by the inherently higher relapse risk after
auto-HCT, which does not diminish over time.Table 5
Landmark Analysis of Patients Surviving Two Years Free of Progression after
Transplantation
Outcome n RR 95% CI
Lower
Limit
95% CI
Upper
Limit
P Value
NRM
Allo-HCT 138 1
Auto-HCT 138 .90 .36 2.22 .82
Extranodal involvement
Yes 44 1
No 232 .27 .11 .66 .004
Progression/relapse
Allo-HCT 138 1
Auto-HCT 138 7.35 3.10 17.42 <.0001
PFS
Allo-HCT 138 1
Auto-HCT 138 3.23 1.87 5.58 <.0001
Extranodal involvement
Yes 44 1
No 232 .40 .22 .71 .002
OS
Allo-HCT 138 1
Auto-HCT 138 2.09 1.04 4.22 .04
Extranodal involvement
Yes 44 1
No 232 .31 .15 .65 .002Interestingly, the survival curves in our study are remi-
niscent of those seen in the pre-rituximabeera CIBMTR
study comparing auto-HCT against allo-HCT in a much
younger patient cohort [12]. This not only conﬁrms the
impressively low relapse rates in FL after allo-HCT, but also
suggests that over the past decade, NRM associated with
allografting has not changed substantially and remains the
main barrier for the wider application of allo-HCT in FL.
Having said that, compared with the previous CIBMTR study
[12], owing to wider adoption of RIC/NMA strategies, the
allografted FL patients in current study represent a much
older cohort. The improved OS among long-term survivors
after allo-HCT in our analysis are in contrast to the ﬁndings of
National Comprehensive Cancer Network retrospective
study where allo-HCT (n ¼ 49) was associated with higher
mortality [26]. The reasons for this difference are not readily
apparent. Conditioning intensity and GVHD prophylactic
approaches were not available in the National Comprehen-
sive Cancer Network study and could account for observed
differences.
We also evaluated the rates of second malignancies after
both transplantation approaches. Second malignancies are
reported in 5% to 20% of lymphoma patients after auto-HCT
[1-3,27-29] and in 2% to 6% of patients after allo-HCT
[30,31]. Here, we found no signiﬁcant difference in the
incidence of and mortality due to second malignancies
between auto-HCT and allo-HCT; however, second hemato-
logical malignancies were seen predominantly after auto-
HCT.
The therapeutic landscape of relapsed/refractory FL is
undergoing rapid evolution with development of several
novel agents including phosphoinositide 3-kinase (PI3K)
inhibitors [32], Bruton’s tyrosine kinase inhibitors [33], and
ABT-199 (NCT02187861), to name a few. The role and timing
of HCT with greater incorporation of these agents in clinical
practice in the coming years will warrant reappraisal. How-
ever, at the same time, it is important to point out that
patients included in our study appeared enriched for several
high-risk features predicting poor prognosis, where durable
disease control without incorporating HCT would have been
unlikely. For example, the median number lines of therapy
before HCT was 3 to 4, approximately 20% were chemo-
refractory at HCT,w50% were rituximab resistant, and nearly
one-third had a ﬁrst remission lasting <1 year, with the
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Figure 2. Landmark analysis in long-term survivors (24 months). (A) PFS (P
< .0001). (B) OS (P ¼ .0063).
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chemoimmunotherapy era [34,35].
Keeping limitations inherent to registry studies,
including retrospective nature and selection bias, in mind,
our data indicate that in relapsed/refractory FL, either
auto-HCT or allo-HCT, when applied as ﬁrst transplantation
modality, can provide durable disease control. The choice
of the ﬁrst transplantation modality in the current era
should take into account several practical considerations.
The beneﬁts of auto-HCT include disease control with
relatively low morbidity and NRM. These potential ad-
vantages need to be weighed against the continued risk of
relapse and higher risk of second hematological malig-
nancies. At the other end of the decision spectrum, early
NRM and quality-of-life considerations (secondary to
chronic GVHD) remain a limitation with allo-HCT. How-
ever, our data indicate that relapses 2 years after allo-HCT
are rare (Figure 1B), and patients who are able to survive
initial procedure-related toxicities enjoy a long-term sur-
vival beneﬁt (Figure 2B). Using our data derived from
chemoimmunotherapy-treated FL, it is not unreasonable to
support continued use of auto-HCT as ﬁrst transplantation
modality in elderly or less ﬁt patients, especially at an
earlier time point in the disease course (as the auto-HCT
cohort in our analysis was less heavily pretreated). How-
ever, at the same time, our data suggest that in carefully
selected individuals, allo-HCT potentially later in the dis-
ease course can provide (at least) comparable (if not
improved) survival outcomes. Our observations challenge
the practice of considering allografting only in FL patients
failing a prior autograft. At least in younger/more ﬁt pa-
tients, using allo-HCT as the ﬁrst transplantation approach
can not only avoid the costs associated with a prior auto-
HCT, but can also mitigate the not-so-negligible risk of
second hematological malignancies and higher NRM seen
in post-autograft allo-HCTs. It is also worth mentioning
that our data pertain to allografting from matched sibling
or adult URD. Whether these observations can be extrap-
olated to alternative donor (umbilical cord blood or hap-
loidentical) allo-HCT, warrant investigation.In conclusion, our study shows that in grades 1 and 2
relapsed/refractory FL treated with rituximab-based che-
moimmunotherapies, RIC allo-HCT, when applied as the ﬁrst
transplantation modality, is associated with a survival
beneﬁt in long-term survivors.ACKNOWLEDGMENTS
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